Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...
Animal health company Zoetis (NYSE:ZTS) in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, ...
BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...
Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...
Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report). The ...
Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...